Published in Blood on September 06, 2013
Cell biology. Metabolic control of cell death. Science (2014) 1.98
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood (2015) 1.79
Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell (2015) 1.70
Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell (2014) 1.36
Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol (2015) 1.17
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol (2015) 1.12
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene (2015) 1.06
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front Oncol (2014) 1.03
Preventing Allograft Rejection by Targeting Immune Metabolism. Cell Rep (2015) 1.02
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood (2015) 0.92
Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk Res (2015) 0.90
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. Oncotarget (2016) 0.88
Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer (2015) 0.87
Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer. Front Endocrinol (Lausanne) (2014) 0.86
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. Oncotarget (2015) 0.85
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget (2016) 0.85
Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy. J Cancer Sci Ther (2016) 0.81
Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma. Oncotarget (2015) 0.81
Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth. Oncotarget (2016) 0.81
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach. Int J Mol Sci (2015) 0.79
Asparaginase unveils glutamine-addicted AML. Blood (2013) 0.79
Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget (2015) 0.78
Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation. Biochem Biophys Res Commun (2015) 0.78
Glutaminolysis as a target for cancer therapy. Oncogene (2015) 0.78
High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. Sci Rep (2015) 0.78
Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia (2015) 0.77
Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells. Oncotarget (2016) 0.77
Attacking the supply wagons to starve cancer cells to death. FEBS Lett (2016) 0.77
Targeting glutamine uptake in AML. Oncoscience (2014) 0.77
Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics. Int J Cell Biol (2015) 0.76
Intrahippocampal glutamine administration inhibits mTORC1 signaling and impairs long-term memory. Learn Mem (2015) 0.76
Glutaminolysis gets the spotlight in cancer. Oncotarget (2016) 0.75
Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells. Cancer Res (2016) 0.75
The Pasteur's Dictum: Nitrogen Promotes Growth and Oxygen Reduces the Need for Sugar. Front Oncol (2014) 0.75
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma (2015) 0.75
1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell. J Steroid Biochem Mol Biol (2016) 0.75
Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia. Pharmaceuticals (Basel) (2016) 0.75
Bcl-xL inhibition - a novel strategy for glioma therapy. Aging (Albany NY) (2016) 0.75
L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors. Mol Ther Oncolytics (2015) 0.75
Application of Glutamine-enriched nutrition therapy in childhood acute lymphoblastic leukemia. Nutr J (2016) 0.75
High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. EBioMedicine (2016) 0.75
Control of Pim2 kinase stability and expression in transformed human haematopoietic cells. Biosci Rep (2015) 0.75
Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia. Sci Rep (2016) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
ASCT2 (SLC1A5)-Deficient Mice Have Normal B-Cell Development, Proliferation, and Antibody Production. Front Immunol (2017) 0.75
Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast Cancer Res (2017) 0.75
mTOR signaling in growth control and disease. Cell (2012) 29.21
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem (1998) 9.37
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (2010) 6.38
Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci (2010) 6.30
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev (2001) 5.37
Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (2009) 3.14
Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol (2005) 3.12
Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab (2008) 3.03
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol (1997) 2.05
Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol (1998) 1.69
mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood (2005) 1.63
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res (2010) 1.46
A critical role for Lyn in acute myeloid leukemia. Blood (2007) 1.40
Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med (2010) 1.39
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res (1983) 1.39
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia (2011) 1.37
Biochemical and pharmacological studies with asparaginase in man. Cancer Res (1970) 1.34
Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem (2006) 1.29
mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest (2012) 1.27
Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One (2011) 1.22
L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med (1971) 1.21
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res (2012) 1.16
Acidosis-sensing glutamine pump SNAT2 determines amino acid levels and mammalian target of rapamycin signalling to protein synthesis in L6 muscle cells. J Am Soc Nephrol (2007) 1.11
SNAT2 transceptor signalling via mTOR: a role in cell growth and proliferation? Front Biosci (Elite Ed) (2011) 1.07
Targeting autophagy to fight hematopoietic malignancies. Cell Cycle (2010) 1.06
L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun (1999) 1.06
Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood (2006) 1.05
Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J (2001) 1.02
Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer (1970) 0.98
L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets (2011) 0.96
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood (2000) 0.92
Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. Anticancer Res (2007) 0.91
Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem (2005) 0.91
Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res (1969) 0.89
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study. J Clin Oncol (1988) 0.87
In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia. Br J Haematol (2003) 0.84
Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia (2001) 0.83
Characterization of several amino acid transports and glutamine metabolism in MOLT4 human T4 leukemia cells. Clin Lab Haematol (2006) 0.80
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 7.00
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene (2003) 3.96
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res (2010) 2.60
Regulation of cell-cell junctions by the cytoskeleton. Curr Opin Cell Biol (2006) 2.53
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res (2004) 2.52
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol (2009) 2.50
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood (2013) 2.42
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol (2008) 2.20
Measuring patients' perceptions of patient-centered care: a systematic review of tools for family medicine. Ann Fam Med (2011) 2.20
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Multifocal structure of the T cell - dendritic cell synapse. Eur J Immunol (2005) 2.09
Effects of polycythemia on systemic endothelial function in chronic hypoxic lung disease. J Appl Physiol (1985) (2011) 2.04
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica (2007) 2.03
Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res (2010) 2.02
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene (2002) 1.87
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Strength dependence of cadherin-mediated adhesions. Biophys J (2010) 1.86
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood (2007) 1.83
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
Traction forces exerted through N-cadherin contacts. Biol Cell (2006) 1.78
Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood (2012) 1.77
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2006) 1.74
A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood (2013) 1.74
Lamellipodium extension and cadherin adhesion: two cell responses to cadherin activation relying on distinct signalling pathways. J Cell Sci (2003) 1.72
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol (2009) 1.67
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood (2007) 1.67
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene (2004) 1.67
KIF7 mutations cause fetal hydrolethalus and acrocallosal syndromes. Nat Genet (2011) 1.62
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood (2004) 1.60
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle (2011) 1.59
Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature (2006) 1.59
PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep (2012) 1.58
When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res (2012) 1.58
The ciliary pocket: an endocytic membrane domain at the base of primary and motile cilia. J Cell Sci (2010) 1.58
Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma (2013) 1.56
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency? Br J Haematol (2011) 1.55
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica (2006) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell Cycle (2011) 1.53
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood (2009) 1.52
Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma (2011) 1.52
HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell (2005) 1.52
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood (2006) 1.50
A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem (2002) 1.49